Provided by Tiger Trade Technology Pte. Ltd.

TriSalus Life Sciences Inc.

4.15
-0.1600-3.71%
Post-market: 4.150.00000.00%19:30 EDT
Volume:273.18K
Turnover:1.13M
Market Cap:254.42M
PE:-3.12
High:4.27
Open:4.27
Low:4.02
Close:4.31
52wk High:7.95
52wk Low:2.20
Shares:61.31M
Float Shares:43.63M
Volume Ratio:0.61
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.8389
ROE:-496.21%
ROA:-36.75%
PB:38.84
PE(LYR):-2.26

Loading ...

Two new option listings on October 1st

TIPRANKS
·
Yesterday

H.C. Wainwright Keeps Their Buy Rating on TriSalus Life Sciences (TLSI)

TIPRANKS
·
Yesterday

Canaccord Genuity Sticks to Its Buy Rating for TriSalus Life Sciences (TLSI)

TIPRANKS
·
Sep 23

TriSalus Life Sciences Price Target Raised to $12.00/Share from $11.00 by HC Wainwright & Co.

Dow Jones
·
Sep 23

TriSalus Life Sciences, Inc. : H.c. Wainwright Raises Target Price to $12 from $11

THOMSON REUTERS
·
Sep 23

TriSalus Life Sciences Shares Rise 18% Premarket After Co Says Received FDA Clearance for Its Trinav Advance Medical Device

THOMSON REUTERS
·
Sep 23

TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device

Dow Jones
·
Sep 23

TriSalus Life Sciences receives FDA clearance for TriNav Advance

TIPRANKS
·
Sep 23

TriSalus Wins FDA 510(k) Clearance for TriNav Advance Liver Embolization Device

Reuters
·
Sep 23

TriSalus Life Sciences Receives FDA Clearance for Trinav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (Pedd™) Portfolio for Liver Embolization

THOMSON REUTERS
·
Sep 23

TriSalus Life Sciences Inc: Intends to Initiate a Limited Market Release of Trinav Advance Device over Coming Weeks

THOMSON REUTERS
·
Sep 23

TriSalus Life Sciences Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 09

TriSalus Life Sciences, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $11

THOMSON REUTERS
·
Sep 09

TriSalus Life Sciences Joins H.C. Wainwright Global Investment Conference Fireside Chat

Reuters
·
Sep 01

TriSalus Life Sciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

TriSalus Life Sciences Q2 Revenue Beats Estimates

Reuters
·
Aug 07

TriSalus Q2 FY26 Net Loss Narrows 40.74% to $0.16 Per Share; Revenue Rises 1.7% to $11.4 Million

Reuters
·
Aug 07

TriSalus Life Sciences Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $11.407M Beat $10.267M Estimate

Benzinga Earnings
·
Aug 07

TriSalus Life Sciences - Maintains Fy2026 Revenue Guidance of $54 Mln-$57 Mln

THOMSON REUTERS
·
Aug 07

TriSalus Life Sciences Q2 EPS USD -0.16

THOMSON REUTERS
·
Aug 07